-
Maternal age and adverse pregnancy outcomes: a cohort study.
Khalil A, Syngelaki A, Maiz N, Zinevich Y, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:634-43. pdf -
Maternal racial origin and adverse pregnancy outcome: a cohort study.
Khalil A, Rezende J, Akolekar R, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;41:278-85. -
Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia.
Ferreira AF, Rezende JC, de Cassia C Oliveira R, Akolekar R, Nicolaides KH.
J Hum Hypertens 2013;27:261-4. -
Maternal serum insulin-like growth factor-binding protein-3 (IGFBP-3) at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
J Hum Hypertens 2012;26:253-8. -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
Maternal serum insulin-like growth factor-binding protein-1 (IGFBP-1) at 11-13 weeks in pre-eclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Prenat Diagn 2011;31:196-201. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Turning the pyramid of prenatal care.
Nicolaides KH.
Fetal Diagn Ther 2011;29:183-96. -
Maternal serum insulin-like growth factor-I at 11-13 weeks in preeclampsia.
Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH.
Prenat Diagn 2010;30:1026-31.